Skip to content
HowShorted

KalVista Pharmaceuticals, Inc. short interest in 2024

In 2024, KalVista Pharmaceuticals, Inc.'s disclosed short interest ran from 8.00% of shares outstanding on 12 Jan 2024 to 15.07% on 31 Dec 2024, a change of +7.07 percentage points. The year's high was 17.06% on 15 Nov 2024 and its low 7.16% on 31 Jan 2024, averaging 13.27% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 39.53 days on 31 Oct 2024. Full history: KalVista Pharmaceuticals, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for KalVista Pharmaceuticals, Inc. in 2024

2024 in figures

Start of year
8.00% (12 Jan 2024)
End of year
15.07% (31 Dec 2024)
Change
+7.07 pp
High
17.06% (15 Nov 2024)
Low
7.16% (31 Jan 2024)
Average
13.27%
Highest days to cover
39.53 (31 Oct 2024)
SEC filings marked
9

Every report in 2024

KalVista Pharmaceuticals, Inc. short interest in 2024
SettlementShort interestDays to coverFilings since previous
12 Jan 20248.00%6.55
31 Jan 20247.16%5.42
15 Feb 20248.66%1.90
29 Feb 202410.68%4.22results (8-K)
15 Mar 202411.66%7.6510-Q filed, results (8-K)
28 Mar 202413.09%9.14
15 Apr 202413.80%11.99
30 Apr 202413.13%17.06
15 May 202413.65%22.92
31 May 202413.09%17.11
14 Jun 202413.36%24.05
28 Jun 202413.76%10.61
15 Jul 202414.81%16.5010-K filed, results (8-K)
31 Jul 202414.00%19.73
15 Aug 202413.28%32.13
30 Aug 202413.06%18.98
13 Sep 202413.23%16.8410-Q filed, results (8-K)
30 Sep 202415.06%9.86
15 Oct 202415.76%19.82
31 Oct 202415.90%39.53
15 Nov 202417.06%15.92
29 Nov 202416.80%15.23
13 Dec 202414.53%23.3110-Q filed, results (8-K)
31 Dec 202415.07%16.55

See also: KalVista Pharmaceuticals, Inc.'s full history · most shorted US stocks of 2024 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.